FDA approves antifungal Cresemba

FDA approved an NDA from Astellas Pharma Inc. (Tokyo:4503) for oral and IV Cresemba isavuconazonium sulfate to treat

Read the full 186 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE